UP-59 Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: Large, multi-center cohort
Thursday June 27, 2019 from
TBD
Presenter

Dean S. Elterman, Canada

Assistant Professor

Division of Urology

University Health Network, University of Toronto

Abstract

Rezūm water vapor therapy for large volume (≥80 mL) benign prostatic enlargement: Large, multi-center cohort

Dean S. Elterman1, Naeem Bhojani2, Bilal Chughtai3, Kevin C. Zorn2.

1University Health Network, Toronto, ON, Canada; 2University of Montreal Hospital Center, Montreal, QC, Canada; 3Weill Cornell Medical College, New York, NY, United States

Introduction: Open or laser prostatectomy are the standard treatments for benign prostatic hyperplasia (BPH) of large volume prostates ≥80 mL.  Rezūm is a minimally invasive procedure to ablate benign prostatic tissue. Herein, we report the prospective, multi-center results of the largest cohort of prostates ≥80 mL treated with Rezum.

Methods: A prospective registry was established for Rezūm therapy in Canada (2019) at two high-volume centers. All patients had baseline medical and BPH history documented along with uroflowmetry (Qmax and PVR), and validated questionnaires (IPSS, IPSS QoL, BPHII, IIEF-15, MSHQ-EjD function and bother).

Results: 83 patients (mean age 68.7 years) with prostate size ≥80ml were treated with Rezūm from April 2019 to Dec 2020. The average prostate volume was 104.6ml (range 80-160ml) and 65% had a median lobe.  21 patients had prior episode of urinary.  Mean number of injections was 13.6 (range 8-28). Mean duration of procedure was 5.9 minutes (range 2.5-14). Mean duration of post-procedure catheterization was 11.8 days.

IPSS reduced from a baseline score of 20.9 by 24.3% (15.8), 56.7% (9), 59.1% (8.4) at 1, 3, 12 months respectively. IPSS QoL score improved from a baseline of 4.2 to 1.8 (-56%) at 3 months and 1.4 (-70%) at 12 months. Qmax improves from a baseline of 9.2ml/s up to 14.3ml/s (55%) at 3 months. BPHII improved from a baseline of 6.4 to 2.8 (-57%) at 3 months and 1.8 (-71%) at 12 months. IIEF showed no significant change from 52 at baseline to 57 at 12 months. Similarly, no changes in MSHQ function (10.3 to 10.1 at 12 months) or bother (1.4 to 1.3 at 12 months). No Clavien-Dindo  events ≥ grade III occurred. 

Conclusions: Rezum therapy is safe, effective, quick, out-patient procedure in prostate glands ≥80ml with similar outcomes to prostates <80mL.


© 2022 CUA 74th Annual Meeting